Literature DB >> 24579731

Immunosenescence and cancer.

Tamas Fulop1, Anis Larbi2, Jacek M Witkowski3, Rami Kotb4, Katsuiku Hirokawa5, Graham Pawelec6.   

Abstract

The immune system, interacting intimately with the cancer cells in a tumor, may combat or favor cancer development and progression, or both. One of the most important risk factors for solid cancers is age. With increasing age, numerous alterations at multiple levels including molecular, cellular, organ, and systemic are occurring. With age many physiological systems are changing, including the immune system. Several alterations occur in both arms of the immune system with aging. Although the innate immune system shows changes with aging, the most important alterations occur in the adaptive immune system, especially involving T cells. Many changes in the immune system may decrease its capacity to combat the emerging or progressing tumor. Further, the age-related immune changes may favor the cancer development. The most important changes which may decrease the immune response efficiency are the changes in T cell functions and phenotypes, concomitant with the presence of a low-grade inflammation. A consensus is now emerging in oncology that not only the cancer cells themselves should be studied but also their macro- and microenvironments. In this context, the study of the interrelation of the immune response and the tumor at various stages is essential to enhance our capacity for intervention in elderly cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24579731     DOI: 10.1615/critrevoncog.2013010597

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  30 in total

Review 1.  Human T cell immunosenescence and inflammation in aging.

Authors:  Arsun Bektas; Shepherd H Schurman; Ranjan Sen; Luigi Ferrucci
Journal:  J Leukoc Biol       Date:  2017-07-21       Impact factor: 4.962

2.  Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort.

Authors:  Jared C Foster; Jennifer G Le-Rademacher; Josephine L Feliciano; Ajeet Gajra; Drew K Seisler; Ronald DeMatteo; Jacqueline M Lafky; Arti Hurria; Hyman B Muss; Harvey J Cohen; Aminah Jatoi
Journal:  Cancer       Date:  2017-07-12       Impact factor: 6.860

Review 3.  The biology of aging and lymphoma: a complex interplay.

Authors:  Clémentine Sarkozy; Gilles Salles; Claire Falandry
Journal:  Curr Oncol Rep       Date:  2015-07       Impact factor: 5.075

Review 4.  Checkpoint inhibition and melanoma: Considerations in treating the older adult.

Authors:  Claire F Friedman; Jedd D Wolchok
Journal:  J Geriatr Oncol       Date:  2017-05-11       Impact factor: 3.599

5.  Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy.

Authors:  L Golomb; A Sagiv; I S Pateras; A Maly; V Krizhanovsky; V G Gorgoulis; M Oren; A Ben-Yehuda
Journal:  Cell Death Differ       Date:  2015-03-20       Impact factor: 15.828

Review 6.  Immuno-oncology-the new paradigm of lung cancer treatment.

Authors:  D E Dawe; C H Harlos; R A Juergens
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 7.  Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.

Authors:  Vishal Navani; Moira C Graves; Nikola A Bowden; Andre Van Der Westhuizen
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

8.  Comparative analysis of microbial sensing molecules in mucosal tissues with aging.

Authors:  O A Gonzalez; S Kirakodu; M J Novak; A J Stromberg; L Orraca; J Gonzalez-Martinez; A Burgos; J L Ebersole
Journal:  Immunobiology       Date:  2017-10-16       Impact factor: 3.144

Review 9.  Bladder cancer, inflammageing and microbiomes.

Authors:  Austin Martin; Benjamin L Woolbright; Shahid Umar; Molly A Ingersoll; John A Taylor
Journal:  Nat Rev Urol       Date:  2022-07-07       Impact factor: 16.430

Review 10.  A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.

Authors:  Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.